Koch AL, Vellanki PJ, Drezner N, Li X, et al. FDA Approval Summary: Osimertinib for adjuvant treatment of surgically resected non-small cell lung cancer, a collaborative Project Orbis review. Clin Cancer Res 2021 Jul 22. pii: 1078-0432.CCR-21-1034.
PMID: 34301748